



(51) International Patent Classification:

C07D 405/12 (2006.01) A61K 47/10 (2017.01)

C08G 65/331 (2006.01) C07K 5/10 (2006.01)

A61P 35/00 (2006.01) C07K 5/117 (2006.01)

A61K 38/07 (2006.01)

KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2017/034029

(22) International Filing Date:

23 May 2017 (23.05.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/340,926 24 May 2016 (24.05.2016) US

62/485,812 14 April 2017 (14.04.2017) US

(71) Applicant: AMGEN INC. [US/US]; One Amgen Center Dr., Thousand Oaks, California 91320 (US).

(72) Inventors: LUEHR, Gary; 28570 Fox Hollow Drive, Hayward, California 94542 (US). ANIK, Shabbir T.; 1740 Broadway, Apt. 704, San Francisco, California 94109 (US). PENG, Ge; 1002 Solana Drive, Mountain View, California 94040 (US). DOTSENKO, Irina; 1337 Sunny Court Apt 3, San Jose, California 95116 (US). PHIASIVONGSA, Pasit; 2712 Saint Regis Avenue, Brentwood, California 94513 (US). ROMANINI, Dante; 5921 Tobias Avenue, Sherman Oaks, California 91411 (US).

(74) Agent: REDDY, Prabhakar, G. et al.; One Amgen Center Dr., Thousand Oaks, California 91320 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: PEGYLATED CARFILZOMIB COMPOUNDS



Formula I

(57) Abstract: The present invention provides polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I wherein R^1 , R^2 , linker, PEG, n and o are as defined herein. The invention also provides methods of making and using these compounds to treat cancer, and particularly to treat hematological malignancies including multiple myeloma.